SGK3 and Huntington disease: Using an in vivo model of Huntington’s disease (HD), created using nitopropionic acid (3-NPA), CBG efficacy was tested using a dose of 10 mg/kg/day administered i.p. and was shown to have neuroprotective effects by downregulating the proinflammatory markers COX-2, iNOS, IL-6, and TNF-α, by preventing neuronal degradation, downregulating disease-associated genes SgKL and CD44, and normalizing specific protein-1 levels.